Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35252898)

  • 1. An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study.
    Su PL; Chang GC; Hsiao SH; Hsia TC; Lin MC; Lin MH; Shih JY; Yang CT; Yang SH; Chen YM
    JTO Clin Res Rep; 2022 Mar; 3(3):100292. PubMed ID: 35252898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study.
    Jazieh AR; Onal HC; Tan DS; Soo RA; Prabhash K; Kumar A; Huggenberger R; Cho BC
    Ther Adv Med Oncol; 2022; 14():17588359221122720. PubMed ID: 36119641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.
    Wang SY; Lai CH; Chen CW; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Su PL; Lin CC; Su WC
    Thorac Cancer; 2022 Jan; 13(2):182-189. PubMed ID: 34799993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort.
    Aboelhassan R; Sobeih ME; El-Din MA; Ghali RR; El-Din IS; Khorshid O; Mokhtar M; Rabea AM; Belal A; Azim HA; Abdullah M; Elnahas T; Tawfik H; Abdelwahab S; Elsaid AA; Hashem T; Mancy M; Farag H
    Ther Adv Med Oncol; 2023; 15():17588359231212182. PubMed ID: 38028146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study.
    Lee J; Ahn HK; Kim SW; Han JY; Lee SS; Park HS; Lee HW; Kim JH; Cho E; Huggenberger R; Cho BC
    Cancer Med; 2024 Apr; 13(7):e7174. PubMed ID: 38622869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
    BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
    BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
    Su PL; Chen CW; Wu YL; Lin CC; Su WC
    Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
    Xu Y; Ji H; Zhang Y; Xiong L; Han B; Zhong H; Xu J; Zhong R
    Oncologist; 2024 Mar; ():. PubMed ID: 38529688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
    Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
    J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
    Zhai H; Zhong W; Yang X; Wu YL
    Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
    Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
    J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset.
    Prabhash K; Tan DSW; Soo RA; Sitthideatphaiboon P; Chen YM; Voon PJ; Syahruddin E; Chu S; Huggenberger R; Cho BC
    Front Oncol; 2023; 13():1117348. PubMed ID: 37051534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Minami S; Ihara S; Nishimatsu K; Komuta K
    World J Oncol; 2019 Dec; 10(6):187-198. PubMed ID: 31921375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
    Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer.
    Xu K; Liang J; Zhang T; Zhou Z; Chen D; Feng Q; Xiao Z; Hui Z; Lu J; Wang X; Deng L; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
    Thorac Cancer; 2021 Mar; 12(6):814-823. PubMed ID: 33501781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.